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Abstract
Objectives. Relapses affect 30–50% of patients with ANCA-associated vasculitis (AAV) over 5 years,
necessitating long-term treatment. Although there have been studies looking at predictors of relapse in
AAV, this research has yet to translate clinically into guidance on tailored therapy. The aim of this sys-
tematic review was to identify and meta-analyse existing risk factors from the literature and produce a
model to calculate individualised patient risk of relapse.
Method. A search strategy was developed to include all studies identifying predictors of AAV relapse
using multivariate analysis. Individual risk factors were extracted and pooled hazard ratios (HRs) calcu-
lated. A model to predict the time to first relapse based on identified risk factors was tested retrospec-
tively using a cohort of patients with AAV.
Results. The review of 2674 abstracts identified 117 papers for full text review, with 16 eligible for inclu-
sion. Pooled HRs were calculated from significant risk factors, including anti-PR3 ANCA positivity [HR 1.69
(95% CI 1.46, 1.94)], cardiovascular involvement [HR 1.78 (95% CI 1.26, 2.53)], creatinine >200 mmol/l (rela-
tive to creatinine 100) [HR 0.39 (95% CI 0.22, 0.69)] and creatinine 101–200 mmol/l [HR 0.81 (95% CI 0.77,
0.85)]. Using data from 182 AAV patients to validate the model gave a C-statistic of 0.61.
Conclusion. Anti-PR3 ANCA positivity, lower serum creatinine and cardiovascular system involvement
are all associated with an increased risk of relapse, and a combination of these risk factors can be
used to predict the individualised risk of relapse. In order to produce a clinically useful model to strat-
ify risk, we need to identify more risk factors, with a focus on robust biomarkers.
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Introduction
Survival from ANCA-associated vasculitis (AAV) has
improved significantly with the introduction of immuno-
suppressive therapies, changing our perception of
Key messages
. Anti-PR3 ANCA positivity, lower serum creatinine and cardiovascular involvement are associated with increased
risk of relapse.
. A combination of these risk factors can be used to predict individual relapse.
. There is a need to focus on identifying more robust biomarkers to produce a model to predict relapse.
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vasculitides from acutely fatal diseases to chronic re-
lapsing–remitting conditions [1, 2]. Although survival
rates now approach 80% at 5 years, there is still consid-
erable morbidity and mortality associated with AAV; the
mortality ratio remains 2.6 times worse than the age-
and sex-matched general population [3].
Despite initial disease control, relapse occurs in 30–
50% of patients over 5 years, necessitating repeated
courses of immunotherapy and, in many, long-term
treatment [4]. Relapses are associated with accumula-
tion of disease- and treatment-related damage and mor-
bidity [4]. However, prolonged maintenance therapy to
reduce the risk of relapse is also coupled with toxicity
[5]. Current recommendations suggest 24 months of
remission-maintenance therapy once remission has
been achieved, although the optimal duration remains
unknown [6, 7].
Although there have been randomized control trials
(RCTs) and a number of observational studies looking at
clinical, histological and biochemical predictors of re-
lapse in AAV, there is variability in the risk factors identi-
fied, and thus far, no meta-analysis of these has been
performed to quantify their risk [8–10]. Furthermore, this
research has yet to translate clinically into guidance on
tailored therapy dependent on individualised risk of
relapse.
The primary aim of our study was to identify risk fac-
tors for relapse in AAV through a systematic review and
meta-analysis. The secondary aim was to develop a
model to predict the risk of relapse.
Methods
This systematic review protocol was registered with the
International Prospective Register of Systematic
Reviews (PROSPERO) on 28 June 2018 (registration
number: CRD42018102716).
Search strategies
A literature search strategy for MEDLINE and EMBASE
was developed, with the help of a librarian, to include all
studies identifying predictors of AAV relapse from data-
base inception to December 2020. Database-specific
indexing was used for MEDLINE and EMBASE. The main
search concepts were AAV and all its derivatives for dis-
ease terminology combined with relapse/recurrence. We
included only those studies written in English and involv-
ing adult humans. The search strategies can be found in
the supplementary material (for MEDLINE, Supplementary
Table S1, and for EMBASE, Supplementary Table S2,
available at Rheumatology Advances in Practice online).
Abstracts and titles for all studies identified from the
literature search were reviewed by two reviewers (C.K.
and E.K.) for relevance. They had to involve patients
with AAV with reference to risk factors for relapse to be
endorsed for full-paper review. Full papers of selected
abstracts were then assessed independently for eligibil-
ity based on stipulated inclusion and exclusion criteria
(C.K. and K.L.D.), and any disagreements were resolved
by a referee (E.K.). The main inclusion criteria were adult
patients with a new diagnosis of AAV with 12 months
of follow-up. Patients had to have achieved remission
with remission-induction treatment and subsequently re-
ceived maintenance therapy. Studies had to have identi-
fied and quantified independent predictors of AAV
relapse using multivariable analysis or an RCT with re-
lapse or sustained remission as an endpoint. Studies
were excluded if there was no definition of relapse, if
their immunosuppression was not clearly defined with
the induction and maintenance agent and duration, or if
they were a case report, review or conference abstract.
We defined a risk factor as any measurable variable
that was associated with a relapse event during the fol-
low-up period of the study.
Further searches were also performed of the referen-
ces in relevant papers and review articles to identify any
additional studies that might also address the research
question. Where the same study published results for a
risk factor in more than one manuscript, the results from
the most recent publication were used.
Data extraction
For the eligible studies, data were extracted by two
authors (C.K. and K.L.D.) using a standardized form.
Data extracted from the studies included sample size,
sampling frame, data collection, follow-up duration,
study design and aims. Details of induction and mainte-
nance treatment were extracted, along with patient
characteristics including gender, age, anti-PR3 positivity,
BVAS and creatinine at study entry. Outcome data were
extracted on risk factors with their hazard ratio (HR) and
P-values. Where more than one model was presented in
the same study, the model with the greatest number of
significant risk factors was used.
On reviewing the sampling frame from the data-ex-
traction form, it became apparent that there were 11
studies deemed eligible that had included patients from
the same RCTs in their pooled study cohorts. The RCT
cohorts included in more than one eligible study were
CYCAZEREM, CYCLOPS, NORAM, MEPEX, WEGENT
and IMPROVE; many of the original RCTs did not meet
the initial inclusion criteria [11–16]. In order to ensure
that there was no data duplication in the meta-analysis,
further studies were excluded from the meta-analysis af-
ter a sensitivity analysis, assessment of quality using the
Quality In Prognosis Studies (QUIPS) tool and discussion
among all authors. The sensitivity analysis was per-
formed by taking a single risk factor and calculating the
pooled HR based on the inclusion of each duplicated
study.
Statistical analysis
Only those risk factors that were identified in more than
one eligible study were included in the meta-analysis.
Studies presenting risk factors in the form of a HR and
95% CI, or those in which such estimates could be
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derived from the presented statistics, were included in
the meta-analysis. Categorical risk factors were stan-
dardized to the same reference category and continuous
variables to the same units. Pooled HRs for individual
risk factors were calculated using REVMAN software.
Heterogeneity was assessed using I2 statistics.
The quality of the studies was assessed using the
QUIPS tool, which is designed for use in systematic
reviews of prognostic factor studies [17]. QUIPS is com-
posed of six categories to assess the risk of bias: study
participation; study attrition; prognostic factor measure-
ment; outcome measurement; study confounding; and
statistical analysis and reporting. For each study, all six
categories were scored separately as being of high,
moderate or low quality. Assessment of bias was com-
pleted independently by two authors (C.K. and K.L.D.)
for each study included in the meta-analysis, with dis-
agreements being resolved by discussion. All studies
were included in the analysis, but where data duplica-
tion occurred, quality was used to differentiate studies
for inclusion.
We constructed a funnel plot, in which a measure of
the study size was plotted against the HR. We used the
logarithm of the HRs from individual studies and the log-
arithm of precision (1/variance). The distribution on the
funnel plot was used to assess for publication bias and
small-study effect in the meta-analysis.
Concordance statistics were used to validate a model
based on the identified risk factors at diagnosis, using
the data collected retrospectively from the electronic pa-
tient records of 182 patients with AAV under the care of
the vasculitis clinic at University Hospitals Birmingham
National Health Service Foundation Trust in 2018.
Patients were included if they had achieved remission
after induction treatment and if data were available for
the risk factors identified after the meta-analysis. We de-
fined relapse in our cohort as new or worsening disease
activity that required a change in treatment. BVAS was
used to identify organ involvement, but this remained a
clinical decision. Cox regression analysis was applied to
test the possible score combinations of combined risk
factors, with analysis truncated at 5 years of follow-up.
Results
Systematic review
We reviewed 2674 abstracts (1652 EMBASE, 1021
MEDLINE and 1 reference list), of which 2557 were ex-
cluded (Fig. 1A). The complete list of abstracts reviewed
and their outcomes are available on request from the
corresponding author.
One hundred and seventeen full-text studies were
then screened for eligibility. Of these, 101 were ex-
cluded, primarily owing to a lack of multivariate analysis
or poor identification of specific treatment regimens, as
outlined in Fig. 1A.
The 16 studies eligible for the systematic review in-
cluded a total of 2785 patients [8–13, 18–27]. The
studies were published between 2005 and 2018, and
the designs included nine RCTs, five post-hoc analyses
and two cohort studies.
Meta-analysis
Risk factors identified
Thirty risk factors were identified in total from the stud-
ies in the systematic review, of which 21 were identified
in only one study and were not included in the meta-
analysis (Fig. 1B). Thirteen of these single risk factors
were not significant (P> 0.05). As demonstrated in
Fig. 1A, eight full-text articles were excluded because
they identified these single-study risk factors. The sin-
gle-study risk factors are included in Supplementary
Table S3, available at Rheumatology Advances in
Practice online.
Quality assessment
The quality of the remaining nine studies was assessed
using the QUIPS tool. This can be found in
Supplementary Table S4, available at Rheumatology
Advances in Practice online.
None of the studies scored a low risk of bias in all six
quality categories assessed using QUIPS. Study con-
founding was the area with the highest degree of bias
across the studies owing to the variation in confounding
factors assessed in the multivariate analysis of the stud-
ies. Only one RCT remained in the analysis, which
reflects the overall poorer quality of the studies [12].
Studies excluded owing to data duplication
Seven of nine of the remaining studies included patient
cohorts from the same trials, and therefore studies had
to be excluded from the analysis to avoid duplication of
patient data. Supplementary Table S5, available at
Rheumatology Advances in Practice online, summarizes
this duplication of patient cohorts.
The CYCLOPS trial was the most frequently used co-
hort, with four of the eligible studies including patients
from this trial; only one of these could be included in the
meta-analysis [8, 9, 19, 24]. The three largest studies,
with the longest durations of follow-up, were those by
De Joode et al. [19], Walsh et al. [8] and Morgan et al.
[9]; they were all post-hoc analyses including pooled pa-
tient cohorts from multiple trials including CYCLOPS,
each identifying multiple risk factors.
Anti-PR3 ANCA positivity at diagnosis was the most
frequently identified risk factor. Using this risk factor, we
performed a sensitivity analysis (Supplementary Table
S6, available at Rheumatology Advances in Practice on-
line). This demonstrated a difference of only 0.62 be-
tween the largest (2.03) and smallest (1.41) HR, with the
inclusion of the study by Walsh et al. [8] and exclusion
of the other three duplicate studies producing a HR 1.69
(95% CI 1.46, 1.94) with low heterogeneity (I2 7%). The
study by Walsh et al. [8] had the largest sample size in
the systematic review, with 535 patients and a median
follow-up of 40 months. The studies by Walsh et al. [8]
and Morgan et al. [9] were both assessed to have a
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moderate risk of bias using the QUIPs tool, compared
with a high risk in the study by De Joode et al. [19]
(Supplementary Table S4, available at Rheumatology
Advances in Practice online). Overall, our consensus opinion
was that selecting the study by Walsh et al. [8] produced a
more reliable and clinically relevant meta-analysis.
The same process was followed for the WEGENT trial,
excluding the study by Puéchal et al. [20] from further
analysis.
Risk factors included in the meta-analysis
Pulsed vs oral CYC was excluded as a risk factor after
all three of the studies that identified this risk factor
were excluded owing to data duplication [9, 19, 24]. Six
risk factors remained in the meta-analysis identified
from four studies, as listed in Table 1 [8, 18, 22, 25].
Three of these risk factors produced non-significant
(P<0.05) pooled HRs (Table 1). These risk factors were
composed of non-significant HRs from individual studies
and despite pooling, remained non-significant.
The measurement unit of creatinine varied between stud-
ies, making it difficult to pool this relapse risk. Two studies
remaining in the meta-analysis demonstrated the negative
trend for increasing relapse risk with a lower serum creati-
nine at diagnosis, although their units could not be pooled
[8, 18]. Likewise, an additional study in the meta-analysis, by
Pierrot-Deseilligny Despujol et al. [22], identified a reduced
risk of relapse associated with an estimated glomerular filtra-
tion rate <30ml/min. We included the data from the study
by Walsh et al. [8] because this included the larger number
of patients and it graded the risk factor, producing two HRs.
Thus, the meta-analysis identified three significant risk
factors for relapse in patients with AAV, namely anti-
PR3 ANCA positivity (Fig. 2A), cardiovascular system
(CVS) involvement (Fig. 2B) and a lower serum creati-
nine, all at diagnosis.
FIG. 1 Flowcharts demonstrating the number of studies (A) and risk factors (B) identified, screened and included in
the meta-analysis
TABLE 1 All risk factors remaining in the meta-analysis





Anti-PR3 ANCA positive at diagnosis 4 1.69 (1.46, 1.94) <0.00001 7
Lung involvement at diagnosis 3 1.18 (0.90, 1.86) 0.24 0
Age at diagnosis (per year) 3 1.00 (0.99, 1.01) 0.79 84
Cardiovascular system involvement at diagnosis 2 1.78 (1.26, 2.53) 0.001 43
Upper respiratory tract involvement at diagnosis 2 1.39 (0.91, 2.13) 0.13 0
Creatinine at diagnosis >200 mmol/l (relative to creatinine 100 mmol/l)
Creatinine at diagnosis 100–200 mmol/l (relative to creatinine 100 mmol/l)






*Creatinine was identified as a risk factor in two studies, but owing to the different units of measurement the data could
not be pooled and were selected from one study. HR: hazard ratio; n/a: not assessed.
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Publication bias
A funnel plot was constructed for the risk factor shown
in the most studies, anti-PR3 ANCA positivity, in which
a measure of the study size was plotted against the HR.
This was done to detect publication bias or the small-
study effect. We had only four studies plotted on the
chart; therefore, it was difficult to assess for asymmetry
and this has not been included. During the screening for
this review and when assessing the quality of the in-
cluded studies, it became apparent that the HR for non-
significant risk factors was not always published, which
might have introduced an element of reporting bias to
this review.
How useful are risk factors for predicting relapse in
a real-world setting?
Creating the model
The secondary aim of this study was to develop a model
to predict relapse. The three significant risk factors
included in this model were anti-PR3 ANCA positivity
[HR 1.69 (95% CI 1.46, 1.94)], CVS involvement [HR
1.78 (95% CI 1.26,2.53)], creatinine >200 mmol/l (relative
to creatinine 100 mmol/l) [HR 0.39 (95% CI 0.22, 0.69)]
and creatinine 101–200 mmol/l (relative to creatinine
100 mmol/l) [HR 0.81 (95% CI 0.77, 0.85)]. These HRs
were combined to estimate HRs of every combination,
as shown in Supplementary Table S7, available at
Rheumatology Advances in Practice online.
Testing the model
Patient cohort. Data were used from 182 patients with
AAV from a single tertiary centre to validate the model
based on the three risk factors; the patient demo-
graphics of this cohort are shown in Table 2 and com-
pared with the pooled patient cohorts included in the
meta-analysis. One hundred and four (57%) of the
patients relapsed with a median follow-up time of
133 months; 75 (41%) relapsed within 5 years (Table 2).
One hundred and eleven (61%) of the patients were
FIG. 2 Forest plots for risk factors included in the meta-analysis
(A) Relapse risk of pooled hazard ratio for anti-PR3 ANCA positive. (B) Relapse risk of pooled hazard ratio for cardio-
vascular system involvement.
TABLE 2 Comparison of patient demographics of the cohort used to test the model with pooled cohorts from the meta-
analysis
Demographic Patient cohort used
to test model (n 5 182)
Pooled median values from patient
cohorts included in meta-analysis (n 5 1041)
Age at diagnosis, median (range), years 57 (17–85) 59
Male gender, % 58 55
White British ethnicity, % 89 87
Anti-PR3 positive at diagnosis, % 61 64
Creatinine at diagnosis, median (range), mmol/l 146 (44–1137) 190
Cardiovascular involvement at diagnosis, % 6 7
Relapse in first 5 years, % 41 41
Duration of follow-up, median (range), months 133 (7–329) 46
Risk of relapse in ANCA-associated vasculitis
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anti-PR3 positive at diagnosis with a median creatinine
of 146 mmol/l; 33% had a creatinine at diagnosis
100 mmol, 32% 101–200 mmol/l and 35% >200 mmol/l.
Only 11 of 182 patients (6%) had CVS organ involve-
ment at diagnosis.
Concordance statistics. Testing our model using these
data produced a concordance (C-statistic) of 0.61, with
a standard error of 0.029. The model was truncated at
5 years of follow-up; there was a very small improve-
ment in the C-statistic to 0.62, with a standard error of
0.032.
Cox regression. We used Cox regression to assess the
risk of relapse in our cohort of patients relative to the
risk factors present in the patient at diagnosis, as shown
in Table 3. We were unable to test CVS involvement reli-
ably owing to the low incidence rate of 6% in our
patients. We performed Cox regression analysis, trun-
cated at 5 years, for the other six combinations of risk
factors. Comparing the risk of relapse in our patient co-
hort for each possible outcome with the highest risk of
relapse outcome (anti-PR3 ANCA positive and low cre-
atinine), all but one was statistically significant (P<0.05;
Table 3). The HRs estimated from the data were consis-
tent with those derived from the results of the meta-
analysis, as demonstrated in Table 3.
Kaplan–Meier curve for relapse-free survival. The
Kaplan–Meier curve (Fig. 3) demonstrates relapse-free
survival in the 5 years following diagnosis for our
patients for the different combinations of risk factors.
Although there is some overlap on the curve between
outcomes, those patients with the highest risk (i.e. anti-
PR3 positive and low creatinine) are clearly defined. We
did not censor for death for the cumulative relapse-free
survival because none of the patients in our cohort died
without relapsing.
Discussion
This is the first meta-analysis to study risk factors for re-
lapse in AAV. We identified three significant risk factors
from the meta-analysis: anti-PR3 ANCA positivity, CVS
involvement and a lower serum creatinine at diagnosis.
A pooled HR was calculated for each risk factor, which
enabled us to attribute risk to specific combinations of
risk factors in AAV and create a model.
The model we created appeared to be a modest ap-
proximation of relapse risk, but we could not test CVS
involvement reliably within the model because its inci-
dence was rare. We have demonstrated clearly
through the Kaplan–Meier curve that the combination of
TABLE 3 Results of Cox regression analysis of relapse-free survival in the 5 years following diagnosis for our patient
cohort
Risk combination P-value HR (fixed, 95% CI) Theoretical HR calculated
from meta-analysis
High creatinine, anti-PR3 negative, CVS negative 0.002 0.23 (0.09, 0.60) 0.23
High creatinine, anti-PR3 positive, CVS negative 0.002 0.35 (0.19, 0.67) 0.39
Medium creatinine, anti-PR3 negative, CVS negative 0.001 0.22 (0.09, 0.54) 0.48
Medium creatinine, anti-PR3 positive, CVS negative 0.014 0.40 (0.20, 0.83) 0.81
Low creatinine, anti-PR3 negative, CVS negative 0.059 0.45 (0.20, 1.03) 0.59
Low creatinine, anti-PR3 postive, CVS negative Ref. Ref. Ref.
Comparison of relapse risk for the patient cohort calculated through Cox regression analysis, with the theoretical HR for
the same combinations of risk factors identified from the meta-analysis. The theoretical HRs for the risk factor combina-
tions were estimated by multiplying the HRs for the constituent risk factors identified from the meta-analysis. High creati-
nine, >200mmol/l; medium creatinine, 100–200 mmol/l; low creatinine, <100mmol/l. CVS: cardiovascular system; HR: hazard
ratio; Ref.: reference category.
FIG. 3 Kaplan–Meier curve for relapse-free survival dependent on risk factors
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anti-PR3 ANCA positivity and preserved renal function in
patients with AAV carries the greatest risk of relapse.
Clinicians when presented with patients with both risk
factors must consider a prolonged duration of mainte-
nance therapy, but a model based around only two risk
factors is unlikely to be clinically useful.
A previous systematic review by Mukhtyar et al. [28]
looked at outcomes in AAV and identified similar risk
factors for relapse, but a meta-analysis was not per-
formed. Additionally, Tomasson et al. [29] produced a
meta-analysis looking specifically at ANCA measure-
ments during remission to predict relapse. However,
ours is the first meta-analysis identifying multiple risk
factors for relapse in AAV. Multiple studies have shown
that anti-PR3 ANCA-positive patients are at an in-
creased risk of relapse compared with anti-MPO ANCA-
positive patients. Much less explored, and arguably con-
trary to what we might expect, is the reduced relapse
risk associated with poorer renal function. It has been
suggested that this might be attributable to the immune
dysfunction caused by renal failure [30–32].
A strength of this review is testing the model using
our patient cohort. This cohort appears to be compara-
ble to the patient cohorts identified in the meta-analysis,
providing assurance the results are valid (Table 2) [33].
The definition of relapse and cardiovascular organ in-
volvement in our cohort matched each of the studies in-
cluded in the meta-analysis.
Our meta-analysis has several limitations. A substan-
tial proportion of the studies included in the systematic
review had to be excluded from the meta-analysis, pre-
dominantly owing to data duplication. This highlights the
limited data sets we have looking at relapse risk in this
cohort of patients. The evidence for pulsed CYC as a
risk factor for relapse compared with oral CYC is
strongly established; however, this was not included af-
ter all of the studies identifying it were removed owing
to data duplication. Although this is an important risk
factor that is not included in the meta-analysis, we could
not have validated this in the model using our cohort,
because all of our patients are now managed with
pulsed CYC owing to the increased side-effect profile
associated with oral use. In addition, many of the newer
trials, such as RAVE, MAINRITSAN and PEXIVAS,
recruited patients with new and relapsing disease [34–
36]. Relapsing disease was one of the exclusion criteria
for this meta-analysis, because previous relapse can be
a confounding factor to further relapse. There should be
scope for post-hoc analysis of more recent trials, such
as RITUXVAS, to recognize new factors and endorse al-
ready identified factors affecting relapse outcome in
AAV. A greater focus on biomarkers might provide more
robust risk factors.
Excluding studies to account for data duplication
might have introduced bias, but the sensitivity analysis
performed for the risk factors was reassuring. The larg-
est study included in this review contained data from a
pooled post-hoc analysis from multiple RCTs. Including
the data from the original RCTs would have been
preferable, but many of these RCTs did not meet the in-
clusion criteria for the systematic review. Additionally,
pooled analyses looked at multiple risk factors with a
much larger number of patients over a longer period of
follow-up compared with the original RCTs.
We did not include risk factors in the meta-analysis
that were identified in only a single study in order to im-
prove the reliability of the model; many of these were
not significant and, by definition, not therefore a risk fac-
tor. Although excluding significant factors might have in-
troduced selection bias, we do not feel that the addition
of these factors would have changed the clinical useful-
ness of the model.
Initially, patients with Eosinophilic granulomatosis with
polyangiitis (EGPA) were included in our search strategy.
Although EGPA is classified as an AAV, it behaves differ-
ently from Granulomatosis with Polyangiitis and
Microscopic Polysangiitis and it is rarer; therefore, there
has been less research into this subgroup. It became ap-
parent that the predictors of relapse for this vasculitis, such
as eosinophil count and anti-MPO positivity, were different,
and we made a decision to exclude patients with EGPA
from the meta-analysis [37]. Not having stipulated this from
the outset might have introduced selection bias.
A common limitation with meta-analyses is the com-
parability of the cohorts and the appropriateness of the
comparison. The included cohorts differed in terms of
the induction and maintenance treatment and durations,
AAV subgroups and disease severity. None of the four
studies included in the meta-analysis was a RCT. For
these studies, the quality of the multivariate analysis to
identify risk factors was reliant upon adjusting for con-
founding factors, and there was some variation between
studies. Although this is commented on in the quality
assessment of each study, studies were not excluded
entirely based on this quality assessment. Additionally,
relapse risk appears to change over time; there was a
range of follow-up for the studies between 35 and
50 months. When testing the model, we truncated the
follow-up for our cohort of patients to 5 years given that
Cox regression relies on the assumption that the HR
stays the same over time. Despite this variation within
the meta-analysis, the heterogeneity was generally low.
Conclusion
Anti-PR3 positivity, a lower serum creatinine and CVS
involvement at diagnosis are all associated with an in-
creased risk of relapse, and a combination of these risk
factors can be used to predict an individualised relapse
risk. To produce a clinically useful model to stratify risk
and guide the duration of maintenance treatment, we
need to identify a greater number of risk factors, with a
focus towards more robust biomarkers.
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Molecular aspects of T- and B-cell function in uremia.
Kidney Int Suppl 2001;59:S206–11.
31 Cohen G, Rudnicki M, Hörl WH. Uremic toxins modulate
the spontaneous apoptotic cell death and essential
functions of neutrophils. Kidney Int Suppl 2001;78:S48–52.
32 Cohen G, Hörl WH. Immune dysfunction in uremia—an
update. Toxins (Basel) 2012;4:962–90.
33 Pagnoux C, Carette S, Khalidi NA et al. Comparability of
patients with ANCA-associated vasculitis enrolled in
clinical trials or in observational cohorts. Clin Exp
Rheumatol 2015;33(2 Suppl 89):S-77-83.
34 Stone JH, Merkel PA, Spiera R et al. Rituximab versus
cyclophosphamide for ANCA-associated vasculitis. N
Engl J Med 2010;363:221–32.
35 Walsh M, Merkel PA, Jayne DRW. Plasma exchange and
glucocorticoids in severe ANCA-associated vasculitis.
Reply. N Engl J Med 2020;382:2169.
36 Guillevin L, Pagnoux C, Karras A et al.; French Vasculitis
Study Group. Rituximab versus azathioprine for
maintenance in ANCA-associated vasculitis. N Engl J
Med 2014;371:1771–80.
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